The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Share News (N4P)

Share Price Information for N4 Pharma Plc (N4P)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.80
Bid: 0.75
Ask: 0.85
Change: 0.00 (0.00%)
Spread: 0.10 (13.333%)
Open: 0.80
High: 0.80
Low: 0.80
Prev. Close: 0.80
N4P Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: Rio Tinto Up On Plan To Return Sale Proceeds

Thu, 20th Sep 2018 10:30

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.----------FTSE 100 - WINNERS----------Rio Tinto, up 1.9%. The miner intends to return its coal disposal proceeds to shareholders through a USD3.2 billion share buyback programme. The programme will combine an off-market buyback tender targeting up to 41.2 million shares, of around USD1.9 billion, and on-market purchases. Details of the on-market purchases will be set out following the completion of the off-market buyback, which is expected on November 12. The disposal proceeds come from the completed sales of Hail Creek, Valeria and Kestrel, all located in Australia.----------ITV, up 0.4%. Panmure upgraded the media company to a Buy rating from Hold.----------FTSE 100 - LOSERS----------Kingfisher, down 0.7%. The home improvement and garden centres retailer recovered from closing down 6.3% on Wednesday, as a result of a profit drop. For the six months to July 31, Kingfisher posted pretax profit down 30% to GBP281 million from GBP402 million a year ago. On an adjusted basis, pretax profit also fell, by 18% to GBP323 million. Meanwhile, revenue increased 1.2% to GBP6.08 billion compared to GBP6.01 billion a year prior.----------FTSE 250 - WINNERS----------AVEVA Group, up 3.7%. Barclays upgraded the industrial software firm to an Overweight rating from Equal Weight, and also raised the target price to 3,150 pence from 2,800p. AVEVA shares are currently trading at 2,950p. ----------Kier Group, up 4.8%. The infrastructure services swung to a pretax profit of GBP106.2 million in the year to the end of June, swinging from a loss of GBP14.2 million a year earlier as revenue improved by 5% to GBP4.5 billion from GBP4.3 billion. This was due to substantially reduced one off costs to GBP30.7 million from GBP140.3 million the prior year, when the group conducted a portfolio simplification, involving the closure of its Hong Kong and Caribbean operations. On an adjusted basis, pretax profit rose by 9.0% to GBP136.9 million from GBP126.1 million the prior year.----------Weir Group, up 3.0%. Morgan Stanley upgraded the engineering company to an Overweight rating from Equal-Weight, but lowered its price target to 2,120 pence from 2,240p. Weir shares are currently trading at 1,797.0p.----------Inmarsat, up 2.5%. The satellite communications provider agreed a strategic collaboration with Panasonic Avionics Corp to offer broadband in-flight connectivity to the commercial aviation industry, over an initial ten-year period. Under the terms of the agreement, Inmarsat will become Panasonic's exclusive provider of Ka-band in-flight connectivity for commercial aviation, enabling the company to offer high-speed connectivity.----------FTSE 250 - LOSERS----------IG Group Holdings, down 8.8%. The online trading platform provider said revenue in the three months to the end of August declined by 5% to GBP128.9 million on weak performance in the UK and Europe, the Middle East & Africa regions, where revenue fell by 8% and 12%, respectively. The result was hit by a reduction in client numbers. In the UK, the number of clients fell by 13% to 34,000, while the Europe, the Middle East & Africa saw a 10% decrease in client numbers to 27,200.----------OTHER MAIN MARKET AND AIM - WINNERS----------Adept4, up 34%. The IT as a Service provider said it as settled its legal dispute with the vendors of Adept4 Managed IT Ltd, with the verdict being that Adept4 will not pay the deferred payment of GBP1.0 million or the contingent payment of GBP1.5 million to the vendors. In fact, the vendors will pay a cash sum to Adept4 in November, which is expected to result in a small cash flow to the company.----------Lansdowne Oil & Gas, up 18%. The oil and gas company said it has signed a binding farm-out agreement with APEC Energy Enterprises Ltd over the Barryoe oil accumulation, offshore Ireland, With an enhanced multi-well drilling programme of five firm wells and two option wells, preparation work is expected to start immediately, with first drilling expected in the second quarter of 2019. ----------Crimson Tide, up 38%. The company, which provides a workforce management software application called mpro5, signed its first subscription agreements in the Middle East with two clients. "Both companies will be completing maintenance, engineering, and health & safety workflows on mpro5 and the company is hopeful of more wins to come," Crimson said. Furthermore, it announced a contract win with an unnamed USD20 billion US pharma company to provide a patient portal for an anti-cholesterol drug.----------OTHER MAIN MARKET AND AIM - LOSERS----------N4 Pharma, down 38%. The pharmaceutical company, following a strategic review made the decision to close its Genetics division, following a full data report of the clinical trial for the sildenafil reformulation, identifiying that the risk reward profile in reformulate the drug would be too great. As a result, N4 Pharma will focus all its efforts on its Vaccine division, particularly the product Nuvec.----------Minoan Group, down 23%. The travel agency has continued to implement its cost reduction programme, the latest step being the agreement to sell its travel & leisure unit Stewart Travel Ltd to its primary lender Zachary Asset Holdings Ltd for GBP6.6 million in order to reduce debt. However, the group will still need additional funds to pay back its debt to Zachary, which is expected to be GBP900,000 once the sale is completed.----------Petro Matad, down 22%. The Mongolian oil explorer said it has drilling the Snow Leopard-1 well to a total depth of 2,930 metres, however the deeper objective of the well revealed no oil or gas shows, with subsequent logging showing the sediments to be water bearing instead. The Snow-Leopard-1 well will be plugged and abandoned, and the rig used will be moved to the Wild Horse 1 location, which is target 480 million barrels of oil.----------
More News
25 Apr 2024 11:56

N4 Pharma strikes partnership deal for intracellular delivery

(Alliance News) - N4 Pharma PLC on Thursday said it has entered into a collaboration agreement with SRI International Inc.

Read more
23 Apr 2024 13:32

IN BRIEF: N4 Pharma loss widens but "great optimism" remains

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company focused on the development of Nuvec - Posts revenue of GBP1,953 in 2023, compared to no revenue a year ago. Pretax loss widens to GBP1.4 million from GBP1.2 million. Looks ahead to the rest of 2024 with "great optimism."

Read more
18 Apr 2024 12:14

N4 Pharma sees potential in Nuvec delivery method for cancer treatment

(Alliance News) - N4 Pharma PLC on Thursday reported that its novel delivery system for cancer treatment has shown promise, after a successful trial.

Read more
15 Feb 2024 13:17

N4 Pharma shares jump on latest Nuvec developments

(Sharecast News) - N4 Pharma announced a significant advancement in the development of Nuvec, an innovative delivery system tailored for cancer treatments, gene therapy, and vaccines, on Thursday.

Read more
15 Feb 2024 12:06

IN BRIEF: N4 Pharma shares rise on "encouraging" Nuvec research

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company, focused on the development of Nuvec - Reports an "encouraging" update from its Nuvec delivery system for cancer treatments, gene therapy and vaccines. It has completed in-vitro experiments combining epidermal growth factor receptor and polo like kinase 1 molecules onto a Nuvec nanoparticle, before testing it on lung cancer cells. "The work clearly shows that there is a strong beneficial effect at 48 hours on cellular inhibition compared to single dose siRNA, by combining both EGFR and PLK1 onto the same particle," N4 says.

Read more
15 Feb 2024 10:52

AIM WINNERS & LOSERS: DSW warns on earnings amid tepid M&A markets

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Read more
19 Jan 2024 13:00

N4 Pharma's Nuvec granted patent in India

(Sharecast News) - N4 Pharma, a pharmaceutical company developing the cancer vaccine delivery system Nuvec, announced on Friday that it has received confirmation from the University of Queensland regarding the granting of its patent for Nuvec in India.

Read more
19 Jan 2024 09:26

IN BRIEF: N4 Pharma gets India patent for medical delivery system

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company, focused on the development of Nuvec - University of Queensland has informed the company that it has been notified by its Indian patent attorney of the granting of its patent for Nuvec in India. Nuvec is a novel silica nanoparticle delivery system for cancer treatments, gene therapy and vaccines. N4 Pharma says the granted patent in India is for a composition of matter patent for the particle itself, alongside the manufacturing process relating to how the particle is made. Says it matches the patents granted in the US, Canada, Europe, Japan, Australia and China.

Read more
16 Jan 2024 14:05

N4 Pharma subsidiary agrees work programme for glaucoma treatment

(Sharecast News) - N4 Pharma announced a significant development through its subsidiary Nanogenics on Tuesday, after Nanogenics inked a contract to initiate the formulation and sequence selection work for its ECP105 product, aimed at pre-clinical studies at King's College, London.

Read more
16 Jan 2024 13:26

IN BRIEF: N4 Pharma touts contract to test glaucoma treatment, ECP105

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company, focused on the development of Nuvec, a novel silica nanoparticle delivery system, for vaccines and therapeutics - Says subsidiary, Nanogenics Ltd, has signed a contract to start the formulation and sequence selection work to prepare its ECP105 product for testing in pre-clinical studies at King's College, London.

Read more
8 Jan 2024 12:30

N4 Pharma reports progress in Nuvec clinical research

(Sharecast News) - Pharmaceutical delivery system developer N4 Pharma reported significant progress in its research efforts to enhance viral vector performance using Nuvec on Monday.

Read more
8 Jan 2024 09:11

N4 Pharma hails increased efficacy of Nuvec when complexed with AAV8

(Alliance News) - N4 Pharma PLC on Monday said that a series of experiments have shown that Nuvec can deliver increased transduction efficacy, when complexed with Adeno-Associated virus 8.

Read more
18 Dec 2023 16:55

LONDON MARKET CLOSE: FTSE 100 outperforms European peers

(Alliance News) - Stock prices in London closed higher on Monday, after investors shrugged off hawkish comments from US Federal Reserve officials amid festive cheer.

Read more
18 Dec 2023 12:43

N4 Pharma rises on successful results from Nuvec administration

(Alliance News) - N4 Pharma PLC on Monday announced the successful oral administration of Nuvec with a DNA plasmid after receiving promising results from its research programme with the University of Queensland.

Read more
18 Dec 2023 11:17

N4 Pharma upbeat on recent Nuvec developments

(Sharecast News) - N4 Pharma updated the market on Monday on its ongoing research efforts related to Nuvec, its delivery system designed for cancer treatments and vaccines.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.